摘要
目的系统评价西黄丸/西黄胶囊辅助治疗恶性肿瘤的临床有效性和安全性。方法通过计算机对中国知网(CNKI)、中国医院数字图书馆(CHKD)、中国生物医学文献数据库(CBM)、Pub Med外文数据库、EMBASE外文数据库进行检索,搜集关于西黄丸辅助治疗恶性肿瘤的随机对照试验,检索时间从2010年1月至2019年10月。提取资料后采用Cochrane及Jadad评分标准对文献进行质量评价,并采用Review Manager 5.3软件进行Meta分析,应用GRADE系统对结局指标进行质量分级。结果共纳入17个研究,共1 482例患者。Meta分析显示,采用西黄丸/西黄胶囊辅助治疗恶性肿瘤患者,实体瘤疗效评价[RR=1.26,95%CI(1.17,1.36),P<0.05];生活质量评分[MD=10.28,95%CI(7.84,12.72),P<0.05];骨髓抑制反应[RR=0.55,95%CI(0.37,0.84),P<0.05];胃肠道反应[RR=0.6,95%CI(0.49,0.72),P<0.05];肝肾功能异常[RR=0.81,95%CI(0.62,1.06),P=0.12>0.05]。GRADE系统显示实体瘤疗效评价、生活质量评分及骨髓抑制反应质量为低等级,胃肠道反应及肝肾功能异常质量为中等级。结论采用西黄丸/西黄胶囊辅助治疗恶性肿瘤可提高实体瘤疗效及肿瘤患者生活质量,且在产生骨髓抑制反应及胃肠道反应方面低于对照组,但在产生肝肾功能异常方面与对照组相比无差异。
Objective To make a systematic evaluation of the clinical efficacy and safety of Xihuang Pill or Xihuang Capsules in the treatment of malignant tumors.Methods The randomized controlled clinical trials(RCTs)of Xihuang Pills for the treatment of malignant tumors issued in the primary Chinese and foreign databases ofCNKI,CHKD,CBM,Pub Med and EMBASE from January 2010 to October 2019 were retrieved.After theextraction of the data,the quality of the literature was evaluated by Cochrane and Jadad scoring criteria.And thenthe meta-analysis was performed by Revman 5.3 software.The quality of the outcomes was graded by the GRADEsystem.Results A total of 17 RCTs were included,with a total of 1482 patients.The results of meta-analysisshowed that Xihuang Pills or Xihuang Capsules were effective in the treatment of malignant tumors by improvingefficacy for solid tumors[RR=1.26,95%CI(1.17,1.36),P<0.05],quality of life scores[MD=10.28,95%CI(7.84,12.72),P<0.05],myelosuppressive response[RR=0.55,95%CI(0.37,0.84),P<0.05],and gastrointestinal response[RR=0.6,95%CI(0.49,0.72),P<0.05],while had no effect on inducing liver andkidney dysfunction[RR=0.81,95%CI(0.62,1.06),P=0.12>0.05].The GRADE grading showed that thequality of solid tumor efficacy evaluation,quality of life scores and bone marrow suppression response was low,and the quality of gastrointestinal reactions and abnormalities of liver and kidney function was in the medium grade.Conclusion The use of Xihuang Pill or Xihuang Capsules in the treatment of malignant tumors can improve theefficacy for solid tumors and the quality of life of cancer patients,and cause lower incidence of myelosuppressiveresponse and gastrointestinal reactions than the control group.And Xihuang Pill or Xihuang Capsules show nosignificant difference of the incidence of abnormalities of liver and kidney function in comparison with the controlgroup.
作者
游旭军
周青
傅伟
李其信
田雪飞
周兴
吴泳蓉
盛文
YOU Xu-jun;ZHOU Qing;FU Wei;LI Qi-xin;TIAN Xue-fei;ZHOU Xing;WU Yong-rong;SHENG Wen(Hunan University of Chinese Medicine,Changsha 410006 Hunan,China;The First Hospital of Hunan University of Chinese Medicine,Changsha 410011 Hunan,China;Bao’an Traditional Chinese Medicine Hospital,Shenzhen 518101 Guangdong,China)
出处
《中医肿瘤学杂志》
2021年第1期90-96,66,共8页
Journal of Oncology in Chinese Medicine
基金
国家自然科学基金联合基金重点支持项目(编号:U20A20408)
深圳市宝安区科技创新局课题(编号:2020JD536)
深圳市宝安区中医药发展基金会专项(编号:2020KJCX-KTYJ-17)。
关键词
西黄丸
恶性肿瘤
临床疗效
生活质量
不良反应
META分析
Xihuang Pills
malignant tumors
clinical efficacy
quality of life
adverse reactions
meta-analysis